Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition
Mahmoud Toulany et al.
CANCER BIOLOGY & THERAPY (2014)
Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition
Mahmoud Toulany et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence
Hae Yun Nam et al.
AUTOPHAGY (2013)
Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation
Yikun Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs-Dependent DNA Double-Strand Break Repair
Mahmoud Toulany et al.
MOLECULAR CANCER RESEARCH (2012)
Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
George J. Cerniglia et al.
MOLECULAR PHARMACOLOGY (2012)
MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks
Michael Fraser et al.
CELL CYCLE (2011)
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells
Nicole Grabinski et al.
CELLULAR SIGNALLING (2011)
Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Victor M. Rivera et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The mTOR Inhibitor Rapamycin Suppresses DNA Double-Strand Break Repair
Honghong Chen et al.
RADIATION RESEARCH (2011)
In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status
Laura Myllynen et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Autophagy contributes to resistance of tumor cells to ionizing radiation
Hassan Chaachouay et al.
RADIOTHERAPY AND ONCOLOGY (2011)
The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining
Malte Kriegs et al.
DNA REPAIR (2010)
Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
Yoko Nagata et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
Targeting Epidermal Growth Factor Receptor-Associated Signaling Pathways in Non-Small Cell Lung Cancer Cells: Implication in Radiation Response
Eun Jung Choi et al.
MOLECULAR CANCER RESEARCH (2010)
Phosphorylation of IRS proteins, insulin action, and insulin resistance
Sigalit Boura-Halfon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Targeting HER2 signaling pathway for radiosensitization Alternative strategy for therapeutic resistance
Mina No et al.
CANCER BIOLOGY & THERAPY (2009)
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells
Sarah E. Golding et al.
CANCER BIOLOGY & THERAPY (2009)
EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma
Bipasha Mukherjee et al.
CANCER RESEARCH (2009)
Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
James D. Murphy et al.
CLINICAL CANCER RESEARCH (2009)
Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
Pat Gulhati et al.
CLINICAL CANCER RESEARCH (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer
Olga C. J. Schuurbiers et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Oscillations of the p53-Akt Network: Implications on Cell Survival and Death
Keng Boon Wee et al.
PLOS ONE (2009)
Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy
Anja Apel et al.
CANCER RESEARCH (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair
Mahmoud Toulany et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival
Lana Bozulic et al.
MOLECULAR CELL (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
Gary D. Kao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells
Carolyn Cao et al.
CANCER RESEARCH (2006)
Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays
Dmitry Klokov et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiorsensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair
Mahmoud Toulany et al.
CLINICAL CANCER RESEARCH (2006)
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer
Jeffrey M. Albert et al.
MOLECULAR CANCER THERAPEUTICS (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
ET Shinohara et al.
ONCOGENE (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Determinants of rapamycin sensitivity in breast cancer cells
WC Noh et al.
CLINICAL CANCER RESEARCH (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
K Yu et al.
ENDOCRINE-RELATED CANCER (2001)